UK markets closed

Mereo BioPharma Group plc (0A9G.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
3.2650+0.2500 (+8.29%)
At close: 06:28PM GMT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3296.10%
S&P500 52-week change 327.86%
52-week high 34.3380
52-week low 30.7059
50-day moving average 33.4727
200-day moving average 32.0195

Share statistics

Avg vol (3-month) 38.64k
Avg vol (10-day) 37.08k
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 8335.29M
% held by insiders 10.51%
% held by institutions 161.41%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -294.66%
Operating margin (ttm)-1,576.50%

Management effectiveness

Return on assets (ttm)-18.98%
Return on equity (ttm)-45.56%

Income statement

Revenue (ttm)10M
Revenue per share (ttm)0.08
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -26.57M
Net income avi to common (ttm)-29.47M
Diluted EPS (ttm)-0.2850
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)57.42M
Total cash per share (mrq)0.08
Total debt (mrq)5.95M
Total debt/equity (mrq)11.78%
Current ratio (mrq)6.72
Book value per share (mrq)0.37

Cash flow statement

Operating cash flow (ttm)-21.13M
Levered free cash flow (ttm)-24.96M